Bullish indicating open at $55-$60, IPO prices at $37
Gil M. Labrucherie, the Chief Financial Officer of Septerna, Inc. (NASDAQ:SEPN), recently acquired a significant amount of common stock in the company. According to a recent SEC filing, Labrucherie purchased a total of 10,000 shares of Septerna stock. The transactions, which took place on February 25 and February 27, 2025, were executed at prices ranging from $5.59 to $5.85 per share, representing an entry point nearly 80% below the 52-week high of $28.99. The total value of these purchases amounted to $56,866. InvestingPro data shows the stock’s RSI indicates oversold conditions, while analysts maintain an optimistic outlook with price targets ranging from $14 to $38.
The shares were acquired indirectly through The Labrucherie Trust, for which Labrucherie serves as trustee. This transaction boosts his total holdings to 40,000 shares, reflecting his continued confidence in Septerna’s prospects. The company maintains a strong liquidity position with a current ratio of 10.08 and more cash than debt on its balance sheet. For more detailed financial metrics and 12 additional exclusive insights, visit InvestingPro.
In other recent news, Septerna, Inc. has announced the discontinuation of its Phase 1 clinical trial for SEP-786, a treatment aimed at hypoparathyroidism, due to severe elevated bilirubin levels in trial participants. Despite this setback, JPMorgan has maintained its Overweight rating on Septerna with a $38 price target, citing that the adverse events did not indicate potential liver injury and emphasizing the company’s plans to resume its clinical program with a new compound. Cantor Fitzgerald also reaffirmed its Overweight rating on Septerna, setting a $50 price target, and highlighted the company’s growth potential in the hypoPTH treatment market, projecting peak global sales for SEP-786 at $820 million. Additionally, Septerna has appointed Gil Labrucherie as its new Chief Financial Officer, who brings extensive experience in finance and legal roles within the biopharmaceutical sector. The company’s CEO, Jeffrey Finer, expressed confidence in Labrucherie’s ability to bolster Septerna’s financial strategy and support its product pipeline. Septerna’s financial position remains strong, with $137.5 million in cash and marketable securities as of September 30, 2024, and proceeds from its IPO expected to fund operations into the second half of 2027. The company continues to focus on developing alternative compounds in its pipeline, including SEP-631, which is being prepared for clinical trials targeting mast cell diseases. These developments underscore Septerna’s ongoing commitment to advancing its drug discovery efforts despite recent challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.